Physician profile
Devapiran Jaishankar
NPI 1225038490
$3,616.46
in general payments reported to CMS, 2019-2025
40 companies · $2,714 in 2025
The $2,714 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.29 · 2023: $21.00 · 2024: $869 · 2025: $2,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,366 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,366.20 |
| Education | $237.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $446.80 | 2024-2025 | Tecvayli, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $338.63 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $246.04 | 2024-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Astrazeneca Pharmaceuticals Lp | $235.31 | 2024-2025 | Enhertu, Lynparza, Calquence |
| Celgene Corporation | $211.70 | 2024-2025 | Reblozyl, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $183.74 | 2024-2025 | Opdivo, Opdualag |
| Pfizer INC. | $174.56 | 2024-2025 | |
| Gilead Sciences, INC. | $160.67 | 2024-2025 | Trodelvy |
| Genentech USA, INC. | $132.73 | 2024-2025 | Polivy, Columvi, Lunsumio |
| Ipsen Biopharmaceuticals, INC | $131.36 | 2024-2025 | Onivyde |
| Regeneron Healthcare Solutions, INC. | $120.00 | 2024-2025 | Libtayo |
| Genzyme Corporation | $116.19 | 2024-2025 | |
| Daiichi Sankyo INC. | $113.53 | 2024-2025 | Enhertu, Datroway, Injectafer |
| Abbvie INC. | $89.42 | 2024-2025 | |
| Astellas Pharma US INC | $83.65 | 2024-2025 | Padcev, Vyloy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $80.54 | 2025 | |
| Eisai INC. | $75.97 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $63.09 | 2024-2025 | Ninlaro |
| Alexion Pharmaceuticals, INC. | $53.57 | 2025 | Ultomiris |
| Incyte Corporation | $52.70 | 2025 | Zynyz, Monjuvi, Jakafi |
| Beone Medicines USA, INC. | $51.06 | 2025 | Tevimbra |
| Genmab U.S., INC. | $48.46 | 2024-2025 | Epkinly |
| Glaxosmithkline, LLC. | $41.32 | 2024 | Ojjaara, Jemperli |
| Sobi, INC | $31.37 | 2025 | |
| Lilly USA, LLC | $30.62 | 2024-2025 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $28.92 | 2025 | Braftovi, Lorbrena, Xalkori |
| Alnylam Pharmaceuticals INC. | $26.13 | 2025 | Givlaari |
| Servier Pharmaceuticals LLC | $22.77 | 2025 | |
| Emd Serono, INC. | $21.10 | 2024 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
| Iovance Biotherapeutics, INC. | $20.88 | 2025 | Amtagvi |
| Exelixis INC. | $20.38 | 2025 | Cabometyx |
| Recordati_rare_diseases_inc. | $20.35 | 2025 | Enjaymo |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Taiho Oncology, INC. | $19.60 | 2024 | |
| Kyowa Kirin, INC. | $18.72 | 2025 | |
| Deciphera Pharmaceuticals INC. | $18.45 | 2024 | Qinlock |
| Caris Mpi, INC. | $16.91 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $15.93 | 2025 | |
| Seagen INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devapiran Jaishankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.